Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Figure modified from Zheng et al (2024), an open access publication
As of September 2023 it is on the FDA's Category 2 list of bulk drug substances that may not be compounded due to significant safety risks, and the agency has scheduled a Pharmacy Compounding Advisory Committee (PCAC) review for July 2026 covering proposed uses in opioid withdrawal, chronic insomnia, and narcolepsy
Review the COAs for this batch below, or browse the full COA library
Psychedelics, as I said before, they nudge the brain into that slightly disordered state
The law raised insurers financial liability for expensive drugs and insurers shifted these costs to consumers
US$ 26.28
US$ 24.17
US$ 21.01
US$ 28.41
US$ 26.23
